Elevation Oncology Inc. (ELEV)
0.26
-0.00 (-0.04%)
At close: Mar 28, 2025, 3:59 PM
0.26
-2.26%
After-hours: Mar 28, 2025, 06:40 PM EDT
-0.04% (1D)
| Bid | 0.25 |
| Market Cap | 15.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.48M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 0.3 |
| Volume | 1,648,581 |
| Avg. Volume (20D) | 2,607,181 |
| Open | 0.26 |
| Previous Close | 0.26 |
| Day's Range | 0.25 - 0.27 |
| 52-Week Range | 0.24 - 5.83 |
| Beta | 1.38 |
About ELEV
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is bas...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 34
Stock Exchange NASDAQ
Ticker Symbol ELEV
Website https://elevationoncology.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ELEV stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 1816.44% from the latest price.
Stock Forecasts1 week ago
-41.82%
Elevation Oncology shares are trading lower after ...
Unlock content with
Pro Subscription
2 months ago
+10.79%
Elevation Oncology shares are trading higher after the company announced it advanced its EO-3021 trial to target advanced gastric and GEJ cancers with improved care.
